These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 26780934)

  • 1. Mutations in TP53 increase the risk of SOX2 copy number alterations and silencing of TP53 reduces SOX2 expression in non-small cell lung cancer.
    Samulin Erdem J; Skaug V; Bakke P; Gulsvik A; Haugen A; Zienolddiny S
    BMC Cancer; 2016 Jan; 16():28. PubMed ID: 26780934
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of SOX2 and Nestin DNA amplification and protein expression with clinical features and overall survival in non-small cell lung cancer: A systematic review and meta-analysis.
    Li Q; Liu F; Zhang Y; Fu L; Wang C; Chen X; Guan S; Meng X
    Oncotarget; 2016 Jun; 7(23):34520-31. PubMed ID: 27150062
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SOX2 mediates cisplatin resistance in small-cell lung cancer with downregulated expression of hsa-miR-340-5p.
    Cui F; Hao ZX; Li J; Zhang YL; Li XK; He JX
    Mol Genet Genomic Med; 2020 May; 8(5):e1195. PubMed ID: 32130794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The candidate oncogene (MCRS1) promotes the growth of human lung cancer cells via the miR-155-Rb1 pathway.
    Liu M; Zhou K; Huang Y; Cao Y
    J Exp Clin Cancer Res; 2015 Oct; 34():121. PubMed ID: 26467212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Downregulation of miR-638 promotes invasion and proliferation by regulating SOX2 and induces EMT in NSCLC.
    Xia Y; Wu Y; Liu B; Wang P; Chen Y
    FEBS Lett; 2014 Jun; 588(14):2238-45. PubMed ID: 24842609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intertumor heterogeneity of non-small-cell lung carcinomas revealed by multiplexed mutation profiling and integrative genomics.
    Tan DS; Camilleri-Broët S; Tan EH; Alifano M; Lim WT; Bobbio A; Zhang S; Ng QS; Ang MK; Iyer NG; Takano A; Lim KH; Régnard JF; Tan P; Broët P
    Int J Cancer; 2014 Sep; 135(5):1092-100. PubMed ID: 24482041
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MicroRNA-383 is a tumor suppressor and potential prognostic biomarker in human non-small cell lung caner.
    Shang Y; Zang A; Li J; Jia Y; Li X; Zhang L; Huo R; Yang J; Feng J; Ge K; Yang Y; Zhang Y; Jiang J
    Biomed Pharmacother; 2016 Oct; 83():1175-1181. PubMed ID: 27551765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Let-7g and miR-21 expression in non-small cell lung cancer: correlation with clinicopathological and molecular features.
    Capodanno A; Boldrini L; Proietti A; Alì G; Pelliccioni S; Niccoli C; D'Incecco A; Cappuzzo F; Chella A; Lucchi M; Mussi A; Fontanini G
    Int J Oncol; 2013 Sep; 43(3):765-74. PubMed ID: 23820752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. By downregulating Ku80, hsa-miR-526b suppresses non-small cell lung cancer.
    Zhang ZY; Fu SL; Xu SQ; Zhou X; Liu XS; Xu YJ; Zhao JP; Wei S
    Oncotarget; 2015 Jan; 6(3):1462-77. PubMed ID: 25596743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Putative stemness markers octamer-binding transcription factor 4, sex-determining region Y-box 2, and NANOG in non-small cell lung carcinoma: A clinicopathological association.
    Upadhyay VA; Shah KA; Makwana DP; Raval AP; Shah FD; Rawal RM
    J Cancer Res Ther; 2020; 16(4):804-810. PubMed ID: 32930122
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased risk of non-small cell lung cancer and frequency of somatic TP53 gene mutations in Pro72 carriers of TP53 Arg72Pro polymorphism.
    Szymanowska A; Jassem E; Dziadziuszko R; Borg A; Limon J; Kobierska-Gulida G; Rzyman W; Jassem J
    Lung Cancer; 2006 Apr; 52(1):9-14. PubMed ID: 16499995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNA-21 (miR-21) represses tumor suppressor PTEN and promotes growth and invasion in non-small cell lung cancer (NSCLC).
    Zhang JG; Wang JJ; Zhao F; Liu Q; Jiang K; Yang GH
    Clin Chim Acta; 2010 Jun; 411(11-12):846-52. PubMed ID: 20223231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TP53 mutational pattern in Spanish and Polish non-small cell lung cancer patients: null mutations are associated with poor prognosis.
    de Anta JM; Jassem E; Rosell R; Martínez-Roca M; Jassem J; Martínez-López E; Monzó M; Sánchez-Hernández JJ; Moreno I; Sánchez-Céspedes M
    Oncogene; 1997 Dec; 15(24):2951-8. PubMed ID: 9416838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The influence of TP53 mutations on the prognosis of patients with early stage non-small cell lung cancer may depend on the intratumor heterogeneity of the mutations.
    Lee SY; Jeon HS; Hwangbo Y; Jeong JY; Park JY; Lee EJ; Jin G; Shin KM; Yoo SS; Lee J; Lee EB; Cha SI; Kim CH; Park JY
    Mol Carcinog; 2015 Feb; 54(2):93-101. PubMed ID: 24038464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Whole genome copy number analyses reveal a highly aberrant genome in TP53 mutant lung adenocarcinoma tumors.
    Bjaanæs MM; Nilsen G; Halvorsen AR; Russnes HG; Solberg S; Jørgensen L; Brustugun OT; Lingjærde OC; Helland Å
    BMC Cancer; 2021 Oct; 21(1):1089. PubMed ID: 34625038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of genetic alterations on outcomes of patients with stage I nonsmall cell lung cancer: An analysis of the cancer genome atlas data.
    Xu S; Wang Y; Ren F; Li X; Ren D; Dong M; Chen G; Song Z; Chen J
    Cancer Med; 2020 Oct; 9(20):7686-7694. PubMed ID: 32857918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DICER1, DROSHA and miRNAs in patients with non-small cell lung cancer: implications for outcomes and histologic classification.
    Díaz-García CV; Agudo-López A; Pérez C; López-Martín JA; Rodríguez-Peralto JL; de Castro J; Cortijo A; Martínez-Villanueva M; Iglesias L; García-Carbonero R; Fresno Vara JA; Gámez-Pozo A; Palacios J; Cortés-Funes H; Paz-Ares L; Agulló-Ortuño MT
    Carcinogenesis; 2013 May; 34(5):1031-8. PubMed ID: 23349018
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MicroRNA-451 functions as a tumor suppressor in human non-small cell lung cancer by targeting ras-related protein 14 (RAB14).
    Wang R; Wang ZX; Yang JS; Pan X; De W; Chen LB
    Oncogene; 2011 Jun; 30(23):2644-58. PubMed ID: 21358675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of miR-150 and miR-3940-5p is reduced in non-small cell lung carcinoma and correlates with clinicopathological features.
    Sun Y; Su B; Zhang P; Xie H; Zheng H; Xu Y; Du Q; Zeng H; Zhou X; Chen C; Gao W
    Oncol Rep; 2013 Feb; 29(2):704-12. PubMed ID: 23228962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deep sequencing of the TP53 gene reveals a potential risk allele for non-small cell lung cancer and supports the negative prognostic value of TP53 variants.
    Deben C; Van den Bossche J; Van Der Steen N; Lardon F; Wouters A; de Beeck KO; Hermans C; Jacobs J; Peeters M; Van Camp G; Rolfo C; Deschoolmeester V; Pauwels P
    Tumour Biol; 2017 Feb; 39(2):1010428317694327. PubMed ID: 28240049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.